Biotech News

Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System

Pulmonx (LUNG)PulmonxClinical readout

Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilation REDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in

Related news

LUNGPulmonx2026-11-18 21:05 EST

Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference

LUNGPulmonx2026-10-28 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

FEMYFEMASYS2026-10-14 13:00 EST

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

JNJJohnson & Johnson2026-10-24 13:01 EST

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

BSXBoston Scientific2026-11-02 19:02 EST

SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

INSMInsmed2026-10-15 11:00 EST

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

PAVMPAVmed2026-11-03 13:15 EST

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

Stock data

Close
2.74 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States